Novartis AG ADR (NVS)vsSmith & Nephew SNATS Inc (SNN)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
SNN
Smith & Nephew SNATS Inc
$30.38
-2.25%
HEALTHCARE · Cap: $12.97B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 818% more annual revenue ($56.58B vs $6.16B). NVS leads profitability with a 23.9% profit margin vs 10.1%. SNN appears more attractively valued with a PEG of 0.63. SNN earns a higher WallStSmart Score of 62/100 (C+).
NVS
Buy51
out of 100
Grade: C-
SNN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+43.0%
Fair Value
$61.96
Current Price
$30.38
$31.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Earnings expanding 70.4% YoY
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Trading at 12.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SNN
The strongest argument for SNN centers on EPS Growth, PEG Ratio. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : SNN
The primary concerns for SNN are Price/Book.
Key Dynamics to Monitor
NVS profiles as a declining stock while SNN is a value play — different risk/reward profiles.
SNN carries more volatility with a beta of 0.74 — expect wider price swings.
SNN is growing revenue faster at 7.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SNN scores higher overall (62/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Smith & Nephew SNATS Inc
HEALTHCARE · MEDICAL DEVICES · USA
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?